Sensus Healthcare, Inc. (SRTS) ended the recent trading session at $5.90, demonstrating a +1.72% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.93%. At the same time, the Dow lost 0.41%, and the tech-heavy Nasdaq lost 1.53%. Prior to today's trading, shares of the company had lost 11.04% over the past month. This has lagged the Medical sector's loss of 3.08% and the S&P 500's gain of 2.17% in that time. The upcoming earnings release of Sensus Healthcare, Inc. ...

Sensus Healthcare, Inc. (SRTS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $5.80, moving -1.86% from the previous trading session. This change lagged the S&P 500's 0.19% loss on the day. At the same time, the Dow added 0.09%, and the tech-heavy Nasdaq lost 0.36%. The company's stock has dropped by 12.83% in the past month, falling short of the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06%. Analysts and investors alike will be keeping a close eye on the performance of Sensus Healthcare, Inc. in it ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Whi ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Sensus Healthcare, Inc. (SRTS) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Sensus Healthcare, Inc. is one of 1017 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank in ...

Shares of Sensus Healthcare, Inc. (SRTS) have gained 1.1% over the past four weeks to close the last trading session at $6.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.67 indicates a potential upside of 65.7%. The average comprises three short-term price targets ranging from a low of $10 to a high of $12, with a standard deviation of $1.15. While the lowest estimate i ...

Slavica/E+ via Getty Images Investment Thesis Sensus Healthcare (NASDAQ:NASDAQ:SRTS) is a company that offers equipment to treat skin problems, including non-melanoma cancer. These products have shown strong demand, but are usually affected during economically unstable periods such as 2020 and 2023, causing years as bad as the previous one. During 2024 the company has been recovering and management has begun exciting initiatives to create recurring revenue streams to provide more stability and also recently ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Sensus Healthcare, Inc. (SRTS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Sensus Healthcare, Inc. is one of 1019 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank conside ...

From a technical perspective, Sensus Healtheare, Inc. (SRTS) is looking like an interesting pick, as it just reached a key level of support. SRTS recently overtook the 20-day moving average, and this suggests a short-term bullish trend. The 20-day simple moving average is a well-liked trading tool because it provides a look back at a stock's price over a 20-day period. Additionally, short- term traders find this SMA very beneficial, as it smooths out short-term price trends and shows more trend reversal sig ...

Financial Performance - Revenues for the three months ended June 30, 2024, were $9.2 million, an increase of 104.4% compared to $4.5 million for the same period in 2023[79] - Gross profit for the three months ended June 30, 2024, was $5.4 million, representing a 107.7% increase from $2.6 million in the same period in 2023[81] - Net income for the three months ended June 30, 2024, was $1.6 million, compared to a net loss of $0.4 million for the same period in 2023[78] - Revenues for the six months ended June 30, 2024, were $20.0 million, an increase of 151.9% compared to $8.0 million for the same period in 2023[83] - Gross profit for the six months ended June 30, 2024, was $12.1 million, an increase of 188.1% from $4.2 million in the same period in 2023[84] Cash Flow and Receivables - Cash and cash equivalents decreased by $4.1 million from December 31, 2023, to June 30, 2024[89] - Accounts receivable increased by $7.7 million from December 31, 2023, primarily due to increased sales and extended payment terms[89] Expenses - Selling and marketing expenses decreased by 37.5% to $1.0 million for the three months ended June 30, 2024, compared to $1.6 million for the same period in 2023[82] - Research and development expenses increased by 12.5% to $0.9 million for the three months ended June 30, 2024, due to a project for a drug delivery system[83] Economic Factors - The company continues to monitor inflationary pressures and is taking actions to minimize its effects on product costs and sales[94]